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Abstract
Background: The Myopia Outcome Study of Atropine in Children
(MOSAIC) aims to explore the efficacy, safety, acceptability and
mechanisms of action of 0.01% unpreserved atropine for myopia control in
a European population.
Methods: MOSAIC is an investigator-led, double-masked,
placebo-controlled, randomised clinical trial (RCT) investigating the
efficacy, safety and mechanisms of action of 0.01% atropine for managing
progression of myopia. During Phase 1 of the trial, 250 children aged 6-16
years with progressive myopia instil eye drops once nightly in both eyes
from randomisation to month 24. From month 24 to 36 participants are
re-randomised in Phase 2 of the trial, into continued 0.01% atropine, and
washout, at 1:1 ratio for those participants initially randomised to the
intervention arm (n=167), during which any potential rebound effects on
cessation of treatment will be monitored. All participants initially assigned to
the placebo (n=83) crossover to the intervention arm of the study for Phase
2, and from month 24 to 36, instil 0.01% atropine eye drops in both eyes
once nightly. Further treatment and monitoring beyond 36 months is
planned (Phase 3) and will be designed dependent on the outcomes of
Phase 1.
Results: The primary outcome measure is cycloplegic spherical equivalent
refractive error progression at 24 months. Secondary outcome measures
include axial length change as well as the rebound, safety and acceptability
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profile of 0.01% atropine. Additional analyses will include the mechanisms
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profile of 0.01% atropine. Additional analyses will include the mechanisms
of action of 0.01% atropine for myopia control.
Conclusions: The generalisability of results from previous clinical trials
investigating atropine for myopia control is limited by the predominantly
Asian ethnicity of previous study populations. MOSAIC is the first RCT to
explore the efficacy, safety and mechanisms of action of unpreserved
0.01% atropine in a predominantly White population.
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article can be found at the end of the article.
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REVISED

Amendments from Version 1

Version 1 (3 reviews) of the manuscript entitled “Myopia Outcome
Study of Atropine in Children (MOSAIC): an investigator-led,
double-masked, placebo-controlled, randomised clinical trial
protocol” describes our cycloplegic protocol in detail, as well
as documenting near visual acuity and binocular vision testing
protocols. Table 1 has been updated to include binocular vision
examination (cover test and TNO stereotesting). The ultimate
design of Phase 2 has been updated in the revised manuscript.
Slit lamp routine is performed pre cycloplegia (not post
cycloplegia), and this is now reflected in the manuscript.
Any further responses from the reviewers can be found at the
end of the article

Introduction
Myopia is expected to affect 2.5 billion people by 2020 and
close to 5 billion by 20501,2. Developed countries in East and
Southeast Asia have the highest prevalence of adolescent myopia, with over 90% of 18 year olds in Singapore and 72% in
China affected3. There is also evidence that myopia prevalence
is increasing in Europe, with myopia affecting almost 50% of 25
to 29 year olds, and the proportion of myopic children more
than doubling in the UK over the last 50 years4–6. Likewise, in
the past 30 years, myopia prevalence has almost doubled in the
United States affecting almost 50% of school-leavers7. Standard
clinical care of myopia progression, however, only addresses
the optical impact of this condition, rather than treating its
underlying biological basis8.
Epidemiological studies indicate that myopia is second only to
age as a risk factor for several eye diseases including glaucoma,
cataract and retinal detachment9, and is the primary risk factor in
myopic maculopathy10. Myopic maculopathy is a leading cause
of blindness throughout Asia11 and has been consistently shown
as a major cause of blindness among the working age population across Europe12–16. Myopic maculopathy is a leading cause
of blindness, there is no available treatment, no proven aetiological
basis and relatively little research funding.
Research in several Asian countries including Singapore,
China, Korea and Taiwan has demonstrated that atropine eye
drops significantly slow myopia progression17–22. A recent network meta-analysis suggests that atropine, at various doses, is
the most effective therapy for controlling refractive error and
axial eye growth progression23. As the risk of complications
increases monotonically with the degree of myopia9, slower
progression has the potential to substantially reduce the prevalence of myopia-related vision impairment and the associated
quality-of-life and socio-economic impacts.
Administered as an eye drop, atropine blocks the muscarinic
receptors in the pupillary sphincter musculature, causing pupillary dilatation (mydriasis) which can induce symptoms of photophobia. Atropine also reduces or paralyses contraction of the
ciliary muscle resulting in blurred proximal vision due to loss
of accommodation (cycloplegia) at its normal 0.5% or 1% clinical dose. The severity and persistence of these atropine effects
are dose-dependent18, hence lower doses would be expected to
have lesser mydriatic and cycloplegic effect. The princi-

pal justification for using 0.01% atropine for myopia control
comes as a serendipitous finding from the Atropine Treatment
Of Myopia 2 (ATOM2) study18. Some of the key findings of
ATOM2 included that 0.01% atropine achieved excellent
control of refractive error progression during the initial treatment
phase18, and ultimately demonstrated the best balance of clinical efficacy and side-effect (cycloplegia and mydriasis related)
profile over the entire five-year study duration24.
There are a number of unresolved issues, however, regarding the
use of atropine as a myopia control measure. Firstly, most of the
atropine studies have been conducted in Asia, thus the results
of which cannot be simply extrapolated to other populations,
particularly given that atropine exhibits a high affinity for
melanin25. Although 0.01% atropine appears to be well tolerated
in a Caucasian population exhibiting light irides26, the longerterm safety, acceptability and efficacy of atropine in a Caucasian
cohort has yet to be defined, indicating the need for suitably
designed clinical trials of low-dose atropine including other
ethnicities. Secondly, the ATOM2 study was not placebocontrolled, while the ongoing Low-Concentration Atropine for
Myopia Progression (LAMP) study was only placebo-controlled
for the first year27.
The suggestion that 0.01% atropine is effective in slowing
refractive changes in myopia progression has led many hospital
ophthalmology departments, particularly in Asia, to switch
from using higher doses to using 0.01% atropine. There is also
increasing uptake of low dose atropine in private ophthalmology
and optometry practice in many parts of the world28. However,
an apparent discordance in the two-year ATOM2 treatment
outcomes is a concern. While 0.01% atropine apparently slowed
refractive error progression, the rate of axial elongation in this
treatment arm during the initial two-year treatment phase was
marginally faster than that observed in the historical controls
of the original ATOM1 placebo control group29. The year one
findings from the LAMP study also suggest a dose response
effect in relation to the impact of atropine on axial growth,
but the lack of placebo control in future years of this study
eliminates the possibility of exploring this issue over a longer
treatment time-course27. The inconsistency between refractive
and axial growth outcomes is an issue that can only be
addressed by a placebo-controlled trial of sufficient duration
to definitively address the use of 0.01% atropine for myopia
control. Other unresolved questions include the site and mode
of action, the optimal concentration and long-term safety of
low dose atropine. Most of the available research has primarily focussed on efficacy of the drug30. Therefore investigations
to assess the effect of atropine on biometric characteristics such
as choroidal thickness31, retinal thickness31, crystalline lens
thickness32,33, anterior chamber depth32,33, optic disc parameters34,
corneal curvature33, and axial length23, should also be prioritised
in order to advance our knowledge in relation to the mechanisms
involved in the regulation of axial elongation.
Past clinical trials investigating atropine as a myopia control
intervention have used preserved atropine formulations17,18,23.
Although it is possible that the preservative component of
the drop may enhance penetration of the drug into the anterior chamber35,36, chronic application of eye drops containing
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preservatives can induce significant cytological and histological
impairment in ocular tissues37–39, potentially leading to toxic
adverse effects and non-tolerance to the eye drop40. Such potential
for chronic damage is not ideal for a drug that may be required
for use over an extended period of time in a paediatric population. Evaluation of the safety and efficacy of an unpreserved
formulation is an important feature of this trial.
The Myopia Outcome Study of Atropine In Children (MOSAIC)
has been designed to address some of these important research
questions. The overarching goal of the MOSAIC trial is to explore
the efficacy, safety, acceptability and mechanisms of action of
0.01% atropine for myopia control in European children. Trial
funding was awarded through the Medical Research Charities
Group (MRCG) and funded by the Health Research Board
(HRB) and Fighting Blindness, a non-profit organisation, under
the MRCG-HRB Joint Funding Scheme [Grant Number: MRCG
2016–13]. The design and methodology of the MOSAIC trial
is outlined herein.

Methods
Management, design and registration
The management team and relevant structures established to
oversee the implementation of MOSAIC, including the data
safety monitoring committee (DSMC), trial steering committee

(TSC) and scientific advisory committee (SAC), are outlined in
Figure 1.
MOSAIC is an investigator-led, double-masked, placebo-controlled, randomised clinical trial (RCT) designed to assess the
efficacy, safety, acceptability and mechanisms of action of
0.01% atropine for controlling myopia in children. The trial
protocol, developed according to Standard Protocol Items Recommendations for Interventional Trials (SPIRIT) guidelines,
is registered on the current controlled trials register with the
International Standard Randomised Controlled Trials Number
36732601 (ISRCTN36732601) on 4 October 2017 and also on
the EudraCTdatabase (2016-003340-37) on the 3 July 2018.
The trial is a single centre study conducted at the Centre for
Eye Research Ireland (CERI) at Technological University Dublin, Ireland. The progress of participants through the phases of
MOSAIC are shown in Figure 2 in the consolidated standards of
reporting trials (CONSORT) diagram41. SPIRIT and CONSORT
reporting checklists for MOSAIC are deposited in TU Dublin’s
ARROW repository (see Reporting guidelines42,43).

Patient and public involvement
The MOSAIC protocol and clinical trial documentation were
designed to maximise the benefits of patient and public involvement (PPI) throughout the clinical trial44. All MOSAIC clinical

Figure 1. MOSAIC support and oversight structures.
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Figure 2. Flow of participants through the MOSAIC clinical trial.
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trial documentation, including consent/assent forms, participant
information leaflets and parental questionnaires, were submitted
through Fighting Blindness for PPI review. The collated feedback was analysed, and the relevant clinical trial documentation
was amended to reflect PPI recommendations.

Research question
To address whether it is clinically justifiable and feasible to
offer atropine eye drops to limit the progression of myopia in a
European population. This will be achieved by determining the
efficacy, safety and acceptability of 0.01% atropine treatment.
Primary outcome measure
Change in spherical equivalent refraction at 24 months measured
by cycloplegic auto-refraction.
Secondary outcome measures
1. Efficacy
• C
 hange in ocular axial length at 24 months measured by
optical low-coherence interferometry.
• C
 hange in spherical equivalent refraction at 12 months
measured by cycloplegic auto-refraction.
• C
 hange in ocular axial length at 12 months measured by
optical low-coherence interferometry.
• P
 ercentage of participants who progress <0.25D (dioptre),
0.25D≤0.75D and >0.75D in 24 months.
• R
 ebound acceleration in myopic refractive error after
cessation of atropine treatment, measured as change in
spherical equivalent refraction and axial length between
24 and 36 months.
2. Mechanisms of action
• Effects on off-axis refraction measured by cycloplegic
auto-refraction at 24 months.
• E
 ffects on ocular growth (including retinal vascular morphology, ocular biometry, corneal topography, anterior
chamber, lens thickness, retinal nerve fibre layer and
choroidal thickness) at 24 months.
3. Safety and acceptability
• Changes in visual performance (distance and near visual
acuity (VA), stereoacuity) at 24 months.
• E
 ffects on ocular physiological response (amplitude of
accommodation, accommodative facility, lag of accommodation, near point of convergence, pupil size and
pupil reactivity) at 24 months.
• Q
 uality of life impact associated with atropine use at
24 months.
• F
 requency of adverse events recorded on study-specific
report forms.
• Participant dropout rate during the trial.
• Compliance with trial medication.

Drug manufacture and supply
Unpreserved atropine 0.01% is supplied by the pharmaceutical
company Nevakar (Nevakar, Inc. 1019 US Highway 202-206,
Building K, NJ Center of Excellence, Bridgewater, NJ 08807,
USA) for the duration of the clinical trial. Nevakar’s contracted
manufacturer, Excelvision, has a current EU GMPD Certificate
and is authorised to manufacture atropine 0.01% and placebo
eye drops on behalf of Nevakar, in accordance with the requirements of the EU Guide to Good Manufacturing Practice. The
eye drops are manufactured at a site authorised for manufacture
of aseptically prepared small volume liquids. Investigational
product labelling, packaging and QP release to the trial centre
is provided by Xerimis.
Trial intervention
The intervention for the trial is 0.01% w/v atropine eyedrops, an
anti-cholinergic agent selective for muscarinic receptors. Unpreserved 0.01% w/v atropine solution is supplied to trial participants as single dose ampoules for daily use. The placebo solution,
identical to the atropine eye drop formulation without the
active ingredient (atropine), is also supplied to trial participants
as single dose ampoules for daily use.
During Phase 1 of MOSAIC, participants instil eye drops (atropine or placebo, per their randomisation status) once nightly
into both eyes from the baseline visit to month 24. This is
followed by re-randomisation in Phase 2, into continued 0.01%
atropine, and washout, at 1:1 ratio for those participants initially
randomised to the intervention arm. Participants are monitored in
this washout period to examine any potential rebound effects on
termination of treatment. All participants initially assigned to the
placebo group then crossover to the intervention arm of the study,
and for the period from month 24 to 36, instil 0.01% atropine eye
drops once nightly. An additional monitoring and re-treatment
phase is planned (Phase 3), the design of which will be informed
by (i) the outcomes of Phase 1, (ii) consultation with our TSC
and SAC, (iii) regulatory approval and (iv) funding availability. To ensure the study population is representative of the Irish
population, recruitment is capped by ethnic background in
accordance with ethnic classifications in the 2016 Irish Census45.

Randomisation
The Mater Misericordiae University Hospital (MMUH) Clinical
Research Centre (CRC) will carry out the stratified randomisation procedure. Participants are allocated to one of the two
intervention groups according to a 2:1 treatment to control
ratio to maximise recruitment success. Allocation is carried out
using block randomisation and stratified according to baseline
refractive error (<-3D or ≥ -3D). A randomisation list for each
strata will be prepared by an independent statistician and will be
stored within the CRC.
A key advantage of block randomisation is that treatment
groups tend to be uniformly distributed by key outcome-related
characteristics and the 2:1 assignment of participants remains
similar at all times46, even if the full quota of participants are
not recruited into the clinical trial. Participants are randomised
to a study number unrelated to treatment assignment. Once
officially enrolled on the trial, participants receive a unique
Page 6 of 28
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study identification number at the baseline visit that is prerandomised to one of the intervention arms.

Masking
Study treatment assignment is double masked during the first
24 months. Atropine and placebo eye drops are packaged identically
before delivery of the investigational product to the trial centre, so that the investigator and participants are unable to identify the contents. Labels on the box containing the ampoules
have a batch number (that does not indicate to the investigator
whether it is atropine or the placebo), study reference number,
participant ID, trial sponsor’s name and contact number, investigator name, site address, expiration date of the eye drop, storage
instructions, and a statement informing the participant that the
drop is for clinical trial use only and is not to be ingested.
No interim analyses are planned. The randomisation code is
only broken after all participants have completed the 24-month
visit and all data have been subjected to a “Blind Review”. This
pre-analysis review, masked to treatment, covers, for example,
decisions concerning the exclusion of participants or data from
the analysis sets, the checking of possible transformations and
definitions of outliers, the addition to the model of important
covariates identified in other recent research, and other factors
that might be of relevant to the data analysis. Decisions
made at this time are described in a report and distinguished
from those made after the study statistician has had access to
the treatment codes when final decisions can be adequately
taken, as masked decisions generally introduce less potential
for bias. Only the DSMC has access to the randomisation
list to determine allocation to atropine or placebo within the
appropriate strata, as well as to facilitate interim trial safety
analyses. To reduce performance and ascertainment bias after randomisation, measures are taken as far as is practical to maintain
investigator masking.

Storage and disposal of study treatment
The trial intervention drug and placebo eye drops are securely
stored at the clinical trial site (CERI). Only the study investigators and the senior research assistant have access to the eye drops.
Study medication, monitored constantly with Bluetooth temperature sensors, is stored at room temperature of 20°C to 25°C,
with minimal excursions permitted. A room temperature log is
maintained at the study site. Subjects and their parent/guardian
are also instructed to store the eyedrops at room temperature
with no exposure to extreme temperatures (such as refrigeration).
Parents are provided with a study treatment kit set at each
visit. Each kit contains a 6-month supply of eye drops consisting of 200-unit dose ampoules. Each 6-month treatment
kit consists of two 3-month boxes and each box consists of
20 aluminium foil pouches. Each foil pouch consists of 5-unit dose
ampoules. Parents are instructed to open one ampoule per day
and administer the eye drop into both eyes of the participant
once nightly. After instillation of the eye drop, the open ampoule
and the remaining contents should be placed in the provided
receptacle that is returned to the study centre for accounting
and proper disposal. All returned ampoules are deposited in
appropriately labelled hazardous waste containers and disposed
of in keeping with chemical waste management policies and

procedures. Parents are provided with an information sheet on
correct eyedrop use. This includes an instruction to start a new
box each month irrespective of how many ampoules remain in
the previous box. A contact phone number is also provided in
the participant’s study information pack as well as the product
label, in case the parent has any queries.

Compliance
The study medication is provided to participants at each study
visit during their treatment period. Parents sign to confirm they
have received the eye drops once dispensed and are asked to
bring trial boxes containing their remaining unused ampoules
on all visits after the baseline visit. Parents are provided with a
list of suggestions to encourage adherence, and are asked to create a nightly calendar reminder, as well as a calendar log of date
and time of eye drop instillation on their phone. Regular phone
and text message contact is maintained with parents throughout
the study duration. Participants and their parents are questioned
regarding adherence at each visit and are constantly reminded
about the importance of adhering to the treatment protocol.
Participants are encouraged to attend all study visits. Follow
up visits are scheduled at 6, 12, 18, 24, 30 and 36 months after
the baseline randomisation visit, +/- 2 weeks. Thus, clinic visits
are scheduled from up to 2 weeks before the check-up date
is due. If the participant does not attend the visit, a new
visit is rescheduled within 4 weeks in the first 12 months of the
trial and within 6 weeks thereafter. Participants are informed
that they may be removed from the trial if they fail to attend
within the defined time period. If a participant is dropped from
the trial for this, or any other reason, arrangements are made
for collecting used and unused ampoules.
The study is to be conducted using an intention-to-treat basis.
The level of compliance with eyedrop use is quantified by
questionnaire (self-report), the eyedrop use calendar log and
quantification of returned ampoules (extended data47). There is
no minimum eyedrop insertion compliance criterion that would
cause removal from the trial, but compliance is controlled for in
statistical analyses and used as a measure of acceptability of the
treatment in our secondary objectives.
Any suspected non-compliance or improper eye drop use results
in encouragement to parents and children as well as offering an electronic daily reminder system for families who have
not instilled the drop as instructed. Evidence of over use is also
discussed with participants and they are re-instructed on proper
use and compliance with the once-nightly protocol.

Sample size calculation
Based on available atropine trial data from Singapore17, along
with Pirenzepine trials data from the USA48, myopia progression in the atropine treatment group is postulated to be -0.25D
per annum, with a standard deviation of ±0.3D at two time points
(12 months and 24 months). Power analysis of these data resulted
in a projected effect difference of 50% between the intervention
versus the placebo control group on myopia progression rate.
The primary outcome for this study is the progression of
myopia over the 2-year trial duration sampled every 6 months.
The analyses of progression of myopia will be a 2x5 repeated
Page 7 of 28
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measures mixed analysis of variance (ANOVA) with the factors
of group (placebo and intervention) and time (0 months,
6 months, 12months, 18 months, 24 months). Conducting a power
analysis for the repeated measures (RM) ANOVA, anticipating a
conservative effect size of 0.3, an alpha of 5%, a power of 95%,
with two groups, five repeated measurements and a correlation
among the repeated measures of 0.9 resulted in a sample
size of 136 with a critical F value of 3.91179. Allowing for
a high potential attrition rate (based on the fact that no trial has
been conducted to completion in a European population, in
whom the acceptability and motivation for long term use remain
unknown), a total of 250 children will be recruited. Of these,
167 children will be randomised to the intervention group and
83 to the placebo group.
The study is powered for the primary outcome. However, for
secondary measures or subgroup analyses, the MOSAIC team will
lead a planned meta-analysis of these data combined with data
from ongoing trials in the UK (CHAMP-UK: ISRCTN99883695)
and Australia (ATOM-Australia: ACTRN12617000598381).
Such a meta-analysis will provide additional statistical power
for subgroup and secondary analyses and allow a more definitive
exploration of the mechanistic components of atropine’s influence
on myopia progression.

Eligibility criteria
Only participants between the ages of six to 16 years inclusive
are eligible to participate in the trial. Additional inclusion
criteria comprise:
1. Refractive criteria
• A spherical equivalent refractive error of -1.0D or worse
• Evidence of myopic progression over the preceding year
• A
 stigmatism less than -2.50D and the least myopic meridian
must be more myopic or equal to -0.50D
• C
 orrected visual acuity of 0.2 logMAR (logarithm of
the minimum angle of resolution) or better in both eyes
• N
 ormal binocular vision, no history of amblyopia or
strabismus
• N
 o previous pharmaceutical or optical myopia control
interventions
2. Health criteria
• Normal intraocular pressure (IOP) (<= 21mmHg)
• N
 ormal ocular health, with no history of glaucoma or
any other ocular diseases or ocular surgery
• No significant or severe corneal damage or scarring
• G
 ood general health with no history of myasthenia gravis
or any cardiac, respiratory, kidney or urinary disease
or dysfunction
• N
 o known allergy to atropine, cyclopentolate hydrochloride
and/or proxymetacaine hydrochloride

• A
 negative pregnancy test for females with childbearing
potential
3. C
 apacity criteria
• Willingness to commit to the duration of the clinical trial
and to accept the possibility of randomisation to the placebo
arm.
• A
 bility of the participant (or parent/guardian) to provide
written informed consent.

Study recruitment
Participants are recruited into this trial through a variety of
channels, each of which were established prior to commencement of the pre-trial phase and are continued throughout the
study until recruitment is complete. These avenues included:
1. N
 ational and local ophthalmic professional engagement:
information leaflets and flyers (containing clinical
trial information including trial eligibility criteria,
see extended data47) were sent to optometrists in the
community advising them of the study and to relate
this information to potential participants and their
parents/guardians49. Information packs (containing information leaflets for optometrists and for parent, as well
as flyers, see extended data47) were also distributed at
various ophthalmic continuing professional development and networking events. Flyers are now displayed
in clinical practices and in the National Optometry
Centre, Dublin, Ireland49.
2. P
 rofessional associations such as the Association of
Optometrists Ireland and Irish College of Ophthalmologists were approached to seek and facilitate involvement of their members in providing information on the
trial to potential participants in hospital, community
practice and public health settings.
3. T
 U Dublin collaborations: The Access and Civic Engagement Office in TU Dublin was utilised to promote
engagement with local schools, while additional school
contacts were used to engage schools outside Dublin.
4. O
 rganised advertising campaign: a parallel media
campaign promoted awareness of the trial. National and
local media were informed of the trial. Radio, newspaper
and online advertisements were disseminated. (http://www.
ceri.ie/assets/information-leaflet_myopia_ceri.pdf., https://
www.rte.ie/brainstorm/2018/0904/991568-what-techis-doing-to-your-eyesight/., https://www.irishtimes.com/
life-and-style/health-family/lifestyle-linked-to-hugeincrease-in-short-sightedness-1.3397726,)
5. A

dedicated project website (http://www.ceri.ie/
myopia-control.html) and social media presence (https://
www.facebook.com/pg/ceri.ie/posts., https://twitter.com/
ceri_dit?lang=en., http://hotsta.org/ceri.ie) maintained by
the project senior research assistant provided information
on the study and promoted the study.
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Informed consent
In compliance with the National Consent Policy of Ireland (2013
-16 Document reference QPSD-D-026-1), parental consent and
child assent (dependent on child age and maturity) is required
before any trial-related procedures are undertaken. Study investigators ensure that parents and children understand the trial
completely including all information on the participant
information leaflet. All study information is available in a childaccessible format. Participants are informed if they are eligible
at the baseline visit. All participants are given the opportunity to
ask any questions about the study prior to parental consent and
child assent being obtained and may withdraw consent at any
time. Participant consent is collected in hardcopy and a copy is
provided to the participants (extended data47).
Study visits
At the baseline visit, each participants’ eligibility is confirmed,
the ability of the parent to instil and participants’ ability to tolerate the instillation of an artificial tear eye drop is assessed. The
participant or parent/guardian is given the allotted atropine or
placebo eye drops to take home and instil one drop every night
into both eyes for the trial duration. After the baseline visit, study
visits are conducted at 6, 12, 18, 24, 30 and 36 months. Each
visit takes approximately 90 minutes. Table 1 summarises the
clinical procedures conducted at each visit.
Description of study assessments
Demographics and inclusion/exclusion criteria. At the initial screening visit all parents are required to complete a
demographic and health questionnaire on behalf of their child
(extended data47). Demographic information includes age,
sex and race. Iris colour is documented50. Medical and ocular
history, including the participant’s GP and optometrist name and
address, is also collected. To participate in the trial, participants
must satisfy all the inclusion and exclusion criteria outlined.
Medical and surgical history. A detailed medical and surgical
case history is undertaken in order to ensure that all trial participants are in good general and ocular health and comply with
the study inclusion and exclusion criteria, including any history
of ocular surgery, amblyopia and patching as well as detailing
any allergies to atropine sulphate, hydroxypropyl methylcellulose,
proxymetacaine hydrochloride or cyclopentolate hydrochloride.
Heart Rate is measured at baseline and every 6 months thereafter until the final study visit. Heart rate is measured with a
heart rate monitor after approximately 3 minutes of rest in the
seated position. The participant is excluded if heart rate is persistently (for more than 10 minutes) > 120 beats per minute at
any study visit.
Females of childbearing potential are required to provide
confirmation of last menstrual period and a negative pregnancy
test. Sexually active participants are advised to use an acceptable,
effective form of contraception until cessation of treatment.

Pre-cycloplegia measures
Visual acuity. Participants’ corrected visual acuity is measured using a randomised letterset of the MultiQuity (MiQ 720)
computerised logMAR chart.

Accommodation and convergence. Amplitude of accommodation (AoA) and near point of convergence (NPC) are measured
non-invasively with a RAF (Royal Air Force) rule using the subjective push-up technique. Measurements are taken both monocularly and binocularly for AoA and binocularly for NPC. Lag of
accommodation to a 40cm (2.5D) target is measured using the
Grand Seiko WAM 5500 open field autorefractor. Accommodative
facility is measured using ±2.00D flippers at near.
Binocular Vision Assessment. With subjects best-corrected
distance spectacle correction in place, the cover-uncover test
and alternating cover test are used to detect the presence of
strabismus or phoria. If movement is present, the direction is
noted and the extent of the phoria is measured using prisms.
Strabismus is an exclusion criterion. The TNO stereoacuity
testing chart is used to evaluate stereopsis.
Near VA. Near visual acuity is documented to monitor any
changes in visual performance. Near visual acuity is determined
as the smallest character size that can be read at 25cms using
best-corrected distance spectacle correction.
Infrared pupillometry. The Topcon ALADDIN optical biometer is used to measure scotopic and photopic pupil size and
pupil reactivity for each participant at each visit. Atropine causes
pupillary dilation, particularly at higher concentrations used in
previous trials. This measure is taken pre- and post-cycloplegia
and is used to determine the physiological impact of 0.01%
atropine on pupillary function as well as to confirm cycloplegia.
Tonometry. An Icare tonometer is used to calculate the
intraocular pressure in both eyes at each study visit pre- and
post-cycloplegia. This measure is taken at all visits as a safety
precaution for participants.
Slit lamp assessment. The slit lamp is used to perform a complete examination of the external eye as a safety precaution
throughout the trial in case of sign of allergy or external abnormality. This includes examination of the cornea, conjunctiva,
iris, pupil, lids and adnexa, relative to the Brien Holden Vision
Institute grading scale where appropiate51. Results are recorded
at each visit study visit, including visits during the washout
period. As the study medication contains phosphates, inclusion in the study requires a healthy cornea with no evidence
of corneal damage or scarring. Cases of corneal calcification
have been reported very rarely in association with the use of
phosphate-containing eye drops in some patients with significantly damaged corneas52,53. The anterior chamber angle
of the eye is checked during slit lamp routine before insertion
of cycloplegic eye drops.
Cycloplegic procedure. One drop of 0.5% topical proxymetacaine hydrochloride is instilled into each eye to achieve topical anaesthesia of the cornea and conjunctiva. This is followed
by instillation of one drop of 1.0% cyclopentolate hydrochloride
in each eye. A second drop of 1.0% cyclopentolate is instilled
in each eye for participants with iris classification green with
brown iris ring (v), peripheral green central brown (vi), brown
with some peripheral green (vii), brown (viii), and dark
brown (ix)3. 15 minutes post cyclopentolate insertion, the
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Table 1. MOSAIC clinical procedures during Phase 1, 2 and 3 of the trial. Abbreviations: Tx, Treatment; *, Only for those participants
who crossover to atropine treatment; **, Only for those participants undergoing re-treatment.
Procedures

Phase 1

Phase 2

Visit 1
Baseline

Visit 2
6
months

Visit 3
12
months

Inclusion/Exclusion
Criteria

✓

✓

✓

✓

✓

Informed Consent

✓

Medical History

✓

Phase 3

Visit 4
Visit 5
Visit 6
Visit 7
Visit 8
Visit 9
18
24 months 6 months 12 months 6 months
12 months
months Finish tx/
into
into
crossover
crossover
crossover crossover crossover washout,
washout,
&
&
monitoring/ monitoring/
washout
washout
re-tx
re-tx

✓

✓

✓

✓

✓

✓

Heart Rate

✓

✓

✓

✓

✓

✓*

✓*

Height

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

Review of Medical History

✓

✓

✓

✓

✓

✓

✓

✓

Weight

✓

Pregnancy Test

✓

Parental Autorefractor

✓

Visual Acuity

✓

Accommodative Lag/
Facility/Amplitude

✓

✓

✓

✓

Near Point of Convergence

✓

✓

✓

✓

Cover test and TNO

✓

✓

✓

✓

Near VA

✓

✓

✓

✓

IR Pupillometry

✓

✓

✓

✓

✓

✓

✓

✓

✓

Tonometry

✓

✓

✓

✓

✓

✓

✓

✓

✓

Objective Refraction

✓

✓

✓

✓

✓

✓

✓

✓

✓

Off-Axis Refraction

✓

✓

✓

✓

✓

✓

✓

✓

✓

Fundus Image

✓

✓

✓

✓

✓

✓

✓

✓

✓

Corneal Topography

✓

✓

✓

✓

✓

✓

✓

✓

✓

Slit lamp Assessment

✓

✓

✓

✓

✓

✓

✓

✓

✓

Ocular Biometry

✓

✓

✓

✓

✓

✓

✓

✓

✓

Optical Coherence
Tomography

✓

✓

✓

✓

✓

✓

✓

✓

✓

Confocal Scanning Laser
Ophthalmoscopy

✓

✓

✓

✓

✓

✓

✓

✓

✓

Adverse event monitoring

✓

✓

✓

✓

✓

✓

✓

✓

Compliance check

✓

✓

✓

✓

✓*

✓*

Questionnaires

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

Dispensing of atropine or
placebo

✓

subject is examined to ensure both pupils are dilating and
amplitude of accommodation is reducing compared to their
pre cycloplegia assessment. If the onset of cycloplegia is not
apparent at 15 minutes, another drop of cyclopentolate
hydrochloride 1% is instilled. Autorefraction is carried out
30 minutes after instillation of the final cycloplegic eye drop.

✓**

✓**

Post cycloplegia measures
Objective refraction. Refractive error and peripheral refractive error are measured by cycloplegic auto-refraction at the
baseline visit using the Grand Seiko WAM 5500 open field
autorefractor. Change in spherical equivalent refraction and
peripheral refraction (30° nasal and temporal) are measured
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by cycloplegic auto-refraction at all
30 minutes post cycloplegic drop insertion.

subsequent

visits

Choroidal thickness. Swept source optical coherence tomography
(OCT) provides a significant improvement over conventional
OCT, in particular, there is better penetration of the deeper
layers of the eye including the choroid. The 7×7 macula scan on
the Topcon DRI OCT Triton, facilitates automated choroidal
thickness mapping at each study visit.
Retinal vasculature. The 7×7 macula and angiography
scans on the Topcon DRI OCT Triton allows imaging of the
central and peripheral retina for detailed analysis of change
in retinal vessels in relation to ocular growth and also to examine and monitor retinal health throughout and after the clinical
trial.
Ocular biometry. The Topcon ALADDIN optical biometer is
used to determine the axial length, anterior chamber depth, pupil
size, keratometry, dynamic pupil measurements, white to white
and lens thickness at the baseline visit. Changes in dynamic
pupil measurements, ocular axial length, anterior chamber depth
and/or lens thickness are documented by repeat measurements
at all subsequent visits.
Adverse event assessments. A detailed adverse events assessment will be conducted at each visit, which includes specific
evaluation as to the experience of known adverse side effects of
topical atropine which can include:
• R
 eading difficulties: some degree of cycloplegia is
anticipated while using 0.01% atropine.
• G
 lare: an increase in pupil size and loss of reactivity is
expected while using 0.01% atropine.
• O
 ther, less common and rare ophthalmic adverse effects
of atropine may include conjunctival irritation, follicular
conjunctivitis, increased intraocular pressure (especially
in patients with closed-angle glaucoma), and swelling
of the eyelids. Participants and parents are provided
with information describing the clinical signs of the
above adverse effects, and given appropriate instruction
as to appropriate management in each case.
• S
 ystemic adverse effects: Tachycardia, dryness of the
mouth, flushing, anhidrosis, heat intolerance or impaired
temperature regulation, hypersensitivity-associated skin
rashes. Participants and parents are provided with information describing the clinical signs of the above adverse
effects and given instruction as to appropriate management
in each case. Heart Rate is measured at baseline and
every six months thereafter until month 24. Heart rate is
monitored at month 30 and 36 for those participants who
have crossed over to atropine treatment.

The detailed examination carried out at each study visit is
used to determine any symptomatic or asymptomatic adverse
responses to atropine use. A detailed case history is also used to
determine the presence of adverse events attributable to the therapeutic intervention. Occurrence of adverse events are recorded
on study-specific adverse report forms. The DSMC review all
adverse events and safety data on a quarterly basis, or more
frequently if required by any emerging safety concerns during the
study.
In the unlikely scenario of a serious adverse event, our team
includes a paediatric ophthalmic surgeon, who will make arrangements for ophthalmic service provision with ophthalmology
and medical colleagues, as appropriate, to manage ophthalmic
adverse events/effects as may be required. Non-ophthalmic
adverse events are managed through appropriate public health
channels including the family physician, emergency services,
accident and emergency unit or other hospital services as may be
required. In the event an unexpected and serious adverse sideeffect is confirmed to be directly attributable to the investigational product, the DSMC, TSC and Study Sponsor will liaise
with the research ethics committee (REC) and Health products Regulatory Authority (HPRA) to determine the appropriate
course of action.

Questionnaires
Lifestyle questionnaire. At each study visit parents are asked
to complete a lifestyle questionnaire to quantify lifestyle habits including outdoors exposure, sports participation, near work
including use of digital technology (see extended data47)49.
Quality of Life Impact questionnaire. The impact or burden
of atropine treatment on the child and the family is assessed
using a validated and atropine specific quality of life questionnaire, adapted from the Parent and New Child Amblyopia
Treatment Index (ATI) questionnaires used with higher atropine
concentrations49,54.

Statistical analysis
Primary efficacy endpoint. The primary outcome, in line with
previous studies17,55, will be myopia progression amongst study
groups, primarily the difference in change in myopic refractive error (in dioptres) from cycloplegic autorefraction from
baseline to month 24. The analysis will rely on parametric
analysis of variance (ANOVA), to control for the effects
of the other continuous variables that are not of primary interest.
The treatment difference in response rate and its 95% confidence
interval (CI) will be provided.
Secondary efficacy endpoints. Univariate analysis will be performed to evaluate the group effect on mean change in axial
length over the 2-year period. Multivariate regression analyses
will be used to assess the association between change in axial
length and progression of myopia while adjusting for treatment effects. The difference in myopic refractive error from
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cycloplegic autorefraction and axial length between the
treatment groups from baseline to visit 6 will be analysed using
RM ANOVA.
The percentage of participants in each treatment group that
progress <0.25D, 0.25D≤0.75D and >0.75D from baseline to
visit 6 will be displayed in cross tabulations.
A post hoc analysis, with Bonferroni correction to account for
any type 1 errors, will be carried out to determine at what timepoint over the 24-month treatment period atropine was most
effective.
The distribution of scores from the quality of life questionnaire is calculated at each visit for all treatment groups. At the
24-month visit the scores for each visit will be calculated and
analysis of variance (ANOVA) and suitable post hoc testing will
be used to determine any statistically significant differences
between the responses at each visit as well as between groups.
Safety and tolerability data will be presented in tables of
descriptive statistics and frequency distribution. RM ANOVA
will be used to detect changes in anterior chamber depth, crystalline lens thickness, retinal nerve fibre layer thickness and
choroidal thickness between treatment groups. A statistical
significance level of p < 0.05 is adopted throughout the analysis.
Adjustment for baseline characteristics will be performed by
analysis of covariance (ANCOVA). Several comparisons will
ensue based on further stratification by a) sex; b) age; c) ethnicity;
d) baseline refractive error and e) baseline axial length, using
data pooled from both eyes, assuming the sample size is
sufficient. The primary statistical analysis will be based on
the intention-to-treat principle, but supported by additional
per-protocol analyses.

Trial steering and oversight
Three committees have been established to provide independent
oversight and steer the strategic direction of the trial.
Data Safety Monitoring Committee
A three-member independent DSMC has been established to
oversee the safety of trial participants. The establishment of the
DSMC is justified given the paediatric population under investigation and the need to detect any potential harm to participants
as early as possible, even though the anticipated potential for
harm in this trial is very low. Safety monitoring will be the
major task for the appointed DSMC. All members of the DSMC
are completely independent of the trial and have no possible
financial or other potential conflict of interest in the study. The
DSMC is composed of a statistician with expertise in biomedical research, a paediatric ophthalmologist and an ophthalmologist
with medical and surgical retina expertise (chairperson).
Trial Steering and Scientific Advisory Committees
In addition to the DSMC, a TSC and SAC has been appointed
to contribute to the design and conduct of the trial. The TSC
includes individuals with expertise and involvement in other atropine trials for myopia control. The SAC includes international
scientists with expertise in the exploration of efficacy, safety

and mechanistic aspects of myopia and its control. The trial
investigators are represented on the Steering Committee by
JL and IF. Together the co-PIs maintain responsibility for all
study design, implementation and oversight across all facets of
the study. The TSC hold teleconference meetings as required.
Meetings address trial strategy, trial protocol and matters arising from the various work packages including staff and other
resource concerns, data collection and all operational issues as
they arise. The scientific and clinical members of the steering
committee have the responsibility of informing the clinical protocol required to effectively and safely implement the
trial, including determination of patient eligibility, examination
protocol, data capture and recording protocol, inter-professional
communication protocol, and decision review protocol. Members
of the TSC and SAC are identified in Figure 1.

Regulatory approval
Regulatory approval for MOSAIC was granted by the Health Products Regulatory Authority (HPRA), reference CT0900/622/001.
Clinical trials in Ireland are currently governed by the
European Communities (Clinical Trials on Medicinal Products for
Human Use) Regulations, 2004, SI No 190 of 2004, transposed
into Irish law the provisions of Council Directive 2001/20/EC.
Ethics
Ethical approval for the study was granted by the Research Ethics
Committee (REC) at the MMUH, Dublin, Ireland (reference
1/478/81), and by the REC at TU Dublin, Ireland (reference
16-45). MOSAIC adheres to the tenets of the Declaration of
Helsinki and follows the full code of ethics with respect to participant recruitment, participant testing and General Data
Protection Regulations (GDPR, effective May 2018).
As required under the EU Directive on Clinical Trials
(European Union - Directive 2001/20/EC), parental or guardian
consent is obtained as required for clinical trials involving
minors, who are defined in this case as persons under the age of
16 years. MOSAIC is carried out within the framework of Children First: National Guidance for the Protection and Welfare
of Children (DCYA, 2011). Child assent is also obtained
in recognition of the importance of the voice of the child in this
type of research56.

Dissemination of findings
Findings and underlying data from MOSAIC will be disseminated at appropriate conferences, through scientific publications
and published in open access format on the TU Dublin ARROW
repository. Findings will also be shared online through social
media channels, blogs, and publications, as well as through
print, broadcast and at stakeholder events.
Study status
Recruiting will being June 2019 and continue through to March
2020.

Discussion
The study that has principally helped to define the approach
and methodology of MOSAIC is the ATOM2 study conducted
in Singapore18,57. The ATOM2 study was designed to examine
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the dose:response characteristics of atropine in terms of its positive impact on myopia progression, and its negative impact
in terms of blurred near vision and photophobia, and demonstrated a beneficial effect of 0.01% atropine on myopia progression
without the adverse effects noted at higher concentrations18.
Specific design limitations of ATOM2 are addressed in the
MOSAIC clinical trial. These include a true placebo group,
increased participant numbers in the 0.01% treatment cohort
and removing the potentially confounding effects of varifocal
glasses that were provided to some of the high-dose groups in
the ATOM2 study.
MOSAIC will investigate the efficacy, safety and acceptability
of 0.01% unpreserved atropine solution for the control of myopia in European (predominantly White) children. The recruitment strategy is a particular strength of the MOSAIC trial, in
that the recruitment by ethnic origin will be capped according to
the demographics within the Irish population according to the
most recent census in order to ensure that results are truly representative of the Irish population. At the 2016 Irish census,
91.7% of the population identified as White45. This approach will
result in the recruitment of an equally high proportion of White
participants with progressive myopia, a group that has yet to
be adequately targeted in relation to the safety and efficacy of
atropine. Future meta-analysis will also permit evaluation of unpreserved 0.01% atropine efficacy and safety compared to preserved
(CHAMP-UK and WA-ATOM) 0.01% atropine.
MOSAIC is also designed to ensure that, at least at the time of
enrolment, each participant exhibits progressive myopia. The
principal benefits of this feature include that (i) this allows a
broader age range of eligible participants which is important
in a European context where myopia onset is typically later
and slower relative to in Asia, (ii) it reduces the possibility that
the outcomes are confounded by variability in the proportion
of naturally non-progressive myopes across treatment arms,
and (iii) it thereby ensures that any differences at the completion
of the trial can be attributed to atropine treatment58.
MOSAIC will provide novel insights into the mechanisms
affecting myopia development, as well as the mechanism of
action of atropine, which still remains unclear59. The MOSAIC
protocol has been made available to other research groups
and is closely replicated in studies in the UK and Australia,
which when pooled for meta-analysis will provide increased
scope to investigate the mechanism of action for atropine’s
anti-myopia effect.

Conclusion
Myopia has become a significant global public health problem. The safety and efficacy of atropine eye drops in reducing myopia progression has been demonstrated in several
clinical trials in Asia; however, due to potential inter-ethnic
differences, the generalisability of such results are limited. The
MOSAIC trial can address significant evidence gaps that exist in
relation to atropine as a myopia control intervention in a

predominantly White population. MOSAIC’s extensive study
design and large sample size are major advantages in determining atropine’s efficacy, mechanism of action and safety
in a Western context. In addition, the planned pooling of
data with similar trials in future meta-analysis will provide
sufficient power for subgroup analysis by age, race, initial
refraction and atropine formulation.

Data availability
Underlying data
No data is associated with this article.

Extended data
ARROW @ TU Dublin: Myopia Outcome Study of Atropine
in Children (MOSAIC): Design and Methodology. https://doi.
org/10.21427/xyq9-ck5347
• 1 Parent consent and information leaflet (2).pdf
(MOSAIC Parent Information Leaflet and Consent Form)
• 2 . Child assent and information leaflet .pdf (MOSAIC
Child Information Leaflet and Assent Form)
• 7 . Eyedrop Questionnaire for Parents- BASELINE
(1).pdf (MOSAIC Baseline Visit Eye Drop Questionnaire
for Parents)
• E
 yedrop QOL Questionnaire for Parents Month 6, 12,
18, 24 (2).pdf (MOSAIC Follow-up Visit Eye Drop
Questionnaire for Parents)
• 8 . Self-reported discomfort Child Sep18 (2).pdf
(MOSAIC Self-Reported Discomfort Questionnaire for
Child)
• 9. MOSAIC Activity diaries .pdf (MOSAIC Activity Diary)
• 5 .mosaic recruitment flyer final.png (MOSAIC Recruitment
Flyer)
• 1 0. STUDY INFORMATION PACK
(MOSAIC Study Information Pack)
• information-leaflet_myopia_ceri.pdf
Information Leaflet for Parents)

(1)

(Myopia

(1).pdf
Control

• information-pack_myopia_ceri.pdf (Myopia Control Information Pack for Optometrists)

Reporting guidelines
ARROW@TU Dublin: CONSORT checklist for ‘Myopia Outcome Study of Atropine in Children (MOSAIC): an investigatorled, double-masked, placebo-controlled, randomised clinical
trial protocol’. https://doi.org/10.21427/3neg-gr7735
ARROW@TU Dublin: SPIRIT checklist for ‘Myopia Outcome
Study of Atropine in Children (MOSAIC): an investigator-led,
double-masked, placebo-controlled, randomised clinical trial
protocol’. https://doi.org/10.21427/2dbf-t10336
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The paper describes a trial for myopia control with low dose atropine in Europeans. There is a need for
these trials as the efficacy of low dose atropine is disputed, not only in Western but also in Asian children.
I have a few questions for the authors for clarification of the introduction, methods and current results.
The introduction states that the ATOM2 achieved excellent control over refractive error progression with
atropine 0.01%. We could debate what would be excellent control however the ATOM2 study found for
this group completely no control over AL progression. Actually, there was more progression in the
treatment group than in the control group. The authors should discuss the dispute rather than the effects
in the non-RCT setup of ATOM after the 2 RCT years. One should carefully study the facts rather than to
praise the partial effects in RCT’s or cohort studies. It is also a fact that the LAMP study only showed 12%
AL growth reduction. Nevertheless this new study should highlight both SER and AL and discuss openly
that in myopia management the AL reduction is the measure we are striving for.
The age range from 6-16 is wide and it is known that myopia progression and especially AL progression
diminishes with age. It is unfortunate that the trial committee did not stratify for age when randomizing.
Could the authors discuss the problems that could arise with the outcome regarding to age and treatment
effect vs. normal progression?
Figure 2 shows a flowchart of the patients in the study. This paper would be the place to discuss what
happened to the excluded patients. For future myopia management studies it is very relevant information.
Could the authors explain in detail all reasons for not participating in this study? Phase 3 describes a
0.02% doses however this is not discussed earlier, please comment.
The eligibility criteria lists evidence of myopic progression over the preceding year. How is this quantified?
Glasses, compared to subjective measurement or is cycloplegia required? AL? Also listed is normal
binocular vision. It is not listed with what test normal correspondence is tested. Is ocular motility or cover
testing preformed? TNO test?
Cycloplegia is confirmed with pupil size, what should be the pupil size and what should be the amplitude
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Cycloplegia is confirmed with pupil size, what should be the pupil size and what should be the amplitude
of accommodation reduction?
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Partly
Are the datasets clearly presented in a useable and accessible format?
Not applicable
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Myopia; pediatric ophthalmology; orthoptics.
I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard, however I have significant
reservations, as outlined above.
Author Response 23 Sep 2019

Saoirse McCrann, Technological University Dublin, Ireland, Dublin, Ireland
Reviewer 3:
The paper describes a trial for myopia control with low dose atropine in Europeans. There is a need
for these trials as the efficacy of low dose atropine is disputed, not only in Western but also in
Asian children. I have a few questions for the authors for clarification of the introduction, methods
and current results.
Reviewer comment 1
The introduction states that the ATOM2 achieved excellent control over refractive error progression
with atropine 0.01%. We could debate what would be excellent control however the ATOM2 study
found for this group completely no control over AL progression. Actually, there was more
progression in the treatment group than in the control group. The authors should discuss the
dispute rather than the effects in the non-RCT setup of ATOM after the 2 RCT years. One should
carefully study the facts rather than to praise the partial effects in RCT’s or cohort studies. It is also
a fact that the LAMP study only showed 12% AL growth reduction. Nevertheless this new study
should highlight both SER and AL and discuss openly that in myopia management the AL
reduction is the measure we are striving for.
Author response 1
Thank you for this observation. ATOM2 did not actually have a control group and used different
methods to measure axial length compared to ATOM1. Comparisons of axial growth outcomes
across the 2 studies are therefore not valid. Our manuscript has, however, already highlighted the
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methods to measure axial length compared to ATOM1. Comparisons of axial growth outcomes
across the 2 studies are therefore not valid. Our manuscript has, however, already highlighted the
reported inconsistency between refractive and axial growth outcomes in both ATOM2 and the
LAMP study. In relation to ATOM2 the manuscript states“ the rate of axial elongation in this
treatment arm during the initial two-year treatment phase was marginally faster than that observed
in the historical controls of the original ATOM1 placebo control group” We recognise the
importance of axial length in myopia management and we hope to definitively address the use of
0.01% atropine for myopia control.
Reviewer comment 2
The age range from 6-16 is wide and it is known that myopia progression and especially AL
progression diminishes with age. It is unfortunate that the trial committee did not stratify for age
when randomizing. Could the authors discuss the problems that could arise with the outcome
regarding to age and treatment effect vs. normal progression?
Author response 2
Following the onset of myopia, the annual rate of myopic progression generally reduces with
age.[1] If the treatment effect of an intervention, in terms of dioptric change or axial length change,
displays a different relationship with age this can lead to misleading impressions of efficacy if
results are reported in percentage terms.[2] For example, a dioptre reduction in progression will
represent a far higher percentage of control in older subjects than it would in younger subjects. The
presentation of results will therefore include absolute changes in refraction and axial length and,
provided that there is a sufficient span of ages, will also be analysed by age.
Reviewer comment 3
Figure 2 shows a flowchart of the patients in the study. This paper would be the place to discuss
what happened to the excluded patients. For future myopia management studies it is very relevant
information. Could the authors explain in detail all reasons for not participating in this study? Phase
3 describes a 0.02% doses however this is not discussed earlier, please comment.
Author response 3
This paper specifically describes the study protocol for MOSAIC which is actively recruiting
participants. We agree participant exclusion is very relevant information, and we aim to publish this
information upon study completion. The description of Phase 2 has now been updated in the
manuscript. A Phase 3 is also planned although the ultimate design of phase 3, including the
possibility to include a higher concentration of atropine, will only be finalised following detailed
analysis of Phase 1 outcomes.
Reviewer comment 4
The eligibility criteria lists evidence of myopic progression over the preceding year. How is this
quantified? Glasses, compared to subjective measurement or is cycloplegia required? AL? Also
listed is normal binocular vision. It is not listed with what test normal correspondence is tested. Is
ocular motility or cover testing preformed? TNO test?
Author response 4
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We are tracking rate of progression in the year(s) preceding study commencement using previous
spectacle prescriptions provided by participants or their eye care professional (typically the
referring practitioner). It is likely that there will be variation in the use of cycloplegia, but we
anticipate that these will typically be non-cycloplegic refraction based. This assessment is not
based on AL.
The binocular vision protocol is now described in the updated manuscript and reads as follows;
“Binocular Vision Assessment. With subjects best-corrected distance spectacle correction in
place, the cover-uncover test and alternating cover test are used to detect the presence of
strabismus or phoria. If movement is present, the direction is noted and the extent of the phoria is
measured using prisms. Strabismus is an exclusion criterion. The TNO stereoacuity testing chart is
used to evaluate stereopsis.”
Reviewer comment 5
Cycloplegia is confirmed with pupil size, what should be the pupil size and what should be the
amplitude of accommodation reduction?
Author response 5
There is no definitive measurement for pupil size and amplitude of accommodation reduction
following cycloplegia. We have now documented our cycloplegic protocol within the manuscript,
which reads as follows;
Cycloplegic procedure. One drop of 0.5% topical proxymetacaine hydrochloride is instilled into
each eye to achieve topical anaesthesia of the cornea and conjunctiva. This is followed by
instillation of one drop of 1.0% cyclopentolate hydrochloride in each eye. A second drop of 1.0%
cyclopentolate is instilled in each eye for participants with iris classification green with brown iris
ring (v), peripheral green central brown (vi), brown with some peripheral green (vii), brown (viii),
and dark brown (ix).[3] 15 minutes post cyclopentolate insertion, the subject is examined to ensure
both pupils are dilating and amplitude of accommodation is reducing compared to their pre
cycloplegia assessment. If the onset of cycloplegia is not apparent at 15 minutes, another drop of
cyclopentolate hydrochloride 1% is instilled. Autorefraction is carried out 30 minutes after
instillation of the final cycloplegic eye drop.
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Jason C. Yam
Department of Ophthalmology and Visual Sciences, Chinese University of Hong Kong, Hong Kong, China
I read with great pleasure on the “Myopia Outcome Study of Atropine in Children (MOSAIC): an
investigator-led, double-masked, placebo-controlled, randomized clinical trial protocol.” The authors are
to be congratulated on launching this important trial.
Summary of the MOSAIC trial.
1. A double-masked, placebo-controlled, randomized clinical trial, on 250 Caucasian children aged 6
- 16.
2. Randomized into two groups: 1) atropine 0.01% once nightly; 2) placebo group once nightly; in 2:1
ratio, for 24 months during phase 1.
3. Atropine treatment group will be washed out, and placebo group crossovered to 0.01% atropine
group during 24 to 36 months during phase 2.
4. Followed up at every 6-months interval under a standardized protocol.
5. Detailed documentation of parameters, including cycloplegic SE, AL, pupil size, accommodation
by RAF, near and distance VA, corneal topography, Choroidal thickness by OCT, fundus images,
questionnaires for side effects etc.
6. Further re-treatment protocol will be planned depending on the outcome of initial phases.
This is a well-designed randomized control trial to answer important clinical questions in using
low-concentration atropine for myopia control. First, this serves as the first RCT of using
low-concentration atropine in European populations. Second, the study has a two-year placebo period,
which will provide more robust evaluation on atropine 0.01%. Third, detailed investigations including
biometric measurement, OCT, retinal image will provide valuable information on the potential anti-myopia
mechanism of low-concentration atropine.
I have a few comments for the authors’ consideration for further enhancement.
Eligibility criteria:
No previous “or current” pharmaceutical or optical myopia control interventions. Those who have
combined treatment should be excluded.
Randomization:
The current randomization is stratified according to baseline refractive error. Given the wide range of
subjects in the study, 6-16, I would suggest to consider to have additional stratification by sex and age.
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subjects in the study, 6-16, I would suggest to consider to have additional stratification by sex and age.
Near VA:
It may be better to specify that “Near visual acuity was assessed using best-corrected distance spectacle
correction”.
Post cycloplegia measurement:
It is important to specify in detail the cycloplegia protocol, as this will influence the clinical outcomes
significantly.
Adverse event assessments:
Need to document the number of subjects wearing photochromic lens.
Questionnaires:
In my opinion, the authors may consider adding a set of visual function questionnaires which may
evaluate better how the visual function under atropine treatment is being affected in the daily life. This is
optional.
Phase two protocol.
I would suggest for authors’ consideration for enhancement. Again, this is optional at the discretion of the
authors.
For phase two, the authors may consider to re-randomize atropine 0.01% group into continued 0.01%
atropine, and washout, at 1:1 ratio, and placebo group remained crossovered to 0.01% atropine group.
This will end up having three groups at 1:1:1 ratio of:
1. Atropine 0.01% continued for three years.
2. Atropine 0.01% for two years, followed by washout one year.
3. Placebo group for two years, followed by atropine 0.01% for one year.
This may better evaluate the rebound effect of 0.01% atropine.
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Myopia, Paediatric Ophthalmology, Genetics, Strabismus
I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard.

Page 21 of 28

HRB Open Research

HRB Open Research 2019, 2:15 Last updated: 12 FEB 2020

Author Response 23 Sep 2019

Saoirse McCrann, Technological University Dublin, Ireland, Dublin, Ireland
Reviewer 2:
This is a well-designed randomized control trial to answer important clinical questions in using
low-concentration atropine for myopia control. First, this serves as the first RCT of using
low-concentration atropine in European populations. Second, the study has a two-year placebo
period, which will provide more robust evaluation on atropine 0.01%. Third, detailed investigations
including biometric measurement, OCT, retinal image will provide valuable information on the
potential anti-myopia mechanism of low-concentration atropine.
I have a few comments for the authors’ consideration for further enhancement.
Reviewer comment 1
Eligibility criteria: No previous “or current” pharmaceutical or optical myopia control interventions.
Those who have combined treatment should be excluded.
Author response 1
Many thanks for your positive comments on the paper. Any previous myopia control intervention is
an exclusion criteria, this includes combined myopia control treatment.
Reviewer comment 2
Randomization: The current randomization is stratified according to baseline refractive error. Given
the wide range of subjects in the study, 6-16, I would suggest to consider to have additional
stratification by sex and age.
Author response 2
Thank you for this comment. As the MOSAIC study has already started it is now too late to stratify
according to sex and age. Our statistical approach will, however, factor these and other variables
into the analysis.
Reviewer comment 3
Near VA: It may be better to specify that “Near visual acuity was assessed using best-corrected
distance spectacle correction”.
Author response 3
This is a valid observation. We have now updated the manuscript to include this.
Reviewer comment 4
Post cycloplegia measurement: It is important to specify in detail the cycloplegia protocol, as this
will influence the clinical outcomes significantly.
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will influence the clinical outcomes significantly.
Author response 4
This is a valid observation. Cycloplegia protocol is now specified in detail in the manuscript and
reads as follows;
Cycloplegic procedure. One drop of 0.5% topical proxymetacaine hydrochloride is instilled into
each eye to achieve topical anaesthesia of the cornea and conjunctiva. This is followed by
instillation of one drop of 1.0% cyclopentolate hydrochloride in each eye. A second drop of 1.0%
cyclopentolate is instilled in each eye for participants with iris classification green with brown iris
ring (v), peripheral green central brown (vi), brown with some peripheral green (vii), brown (viii),
and dark brown (ix).[3] 15 minutes post cyclopentolate insertion, the subject is examined to ensure
both pupils are dilating and amplitude of accommodation is reducing compared to their pre
cycloplegia assessment. If the onset of cycloplegia is not apparent at 15 minutes, another drop of
cyclopentolate hydrochloride 1% is instilled. Autorefraction is carried out 30 minutes after
instillation of the final cycloplegic eye drop.
Reviewer comment 5
Adverse event assessments: Need to document the number of subjects wearing photochromic
lens.
Author response 5
This will be documented as part of MOSAIC’s adverse events assessments.
Reviewer comment 6
Questionnaires: In my opinion, the authors may consider adding a set of visual function
questionnaires which may evaluate better how the visual function under atropine treatment is being
affected in the daily life. This is optional.
Author response 6
Thank you, MOSAIC’s self-reported discomfort questionnaire along with and MOSAIC’s eyedrop
questionnaire for parents incorporate an evaluation of visual function.

Author response 7
Phase two protocol. I would suggest for authors’ consideration for enhancement. Again, this is
optional at the discretion of the authors.
For phase two, the authors may consider to re-randomize atropine 0.01% group into continued
0.01% atropine, and washout, at 1:1 ratio, and placebo group remained crossovered to 0.01%
atropine group. This will end up having three groups at 1:1:1 ratio of:
1. Atropine 0.01% continued for three years.
2. Atropine 0.01% for two years, followed by washout one year.
3. Placebo group for two years, followed by atropine 0.01% for one year.

This may better evaluate the rebound effect of 0.01% atropine.
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This may better evaluate the rebound effect of 0.01% atropine.
Reviewer comment 7
MOSAIC’s scientific committee agree with this excellent suggestion and have revised the ultimate
design of Phase 2 to consist of the 1:1:1 ratio recommended above.
Competing Interests: No competing interests were disclosed.
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Sara McCullough
Optometry and Vision Science Research Group, School of Biomedical Sciences, Biomedical Sciences
Research Institute, University of Ulster, Coleraine, UK
This article describes the methodology for recruitment and data collection for the Myopia Outcome Study
of Atropine in Children (MOSAIC), a double-masked, placebo-controlled, randomised clinical trial. It aims
to determine the efficacy, safety and mechanism of action of 0.01% atropine to slow the progression of
myopia in a predominantly white, European population of children aged six to 16 years of age. Myopic
children with progressing myopia will be recruited to the study and will be randomly assigned to either the
treatment group (0.01% atropine) or the placebo group and will be reviewed every six months for a trial
period of 2 years. The following year will either be a washout period for the treatment group or the placebo
group will receive 0.01% atropine daily. There is clear rationale for the study with the worrying increase in
prevalence of myopia across Europe and the need for a better understanding of treatment therapies for
controlling myopia progression. The majority of previous clinical trials of atropine of varying
concentrations have been conducted in Asian populations where the progression of myopia differs to
white, European children, therefore similar studies need to be replicated to determine specific population
efficacy which will be answered by the proposed study design. The study methods are clearly described
although I had a few specific queries which could be addressed/clarified by the research group to allow
replication by others. There were also some discrepancies between the ‘extended data’ provided that
didn’t tie up with that published in the article.
These include:
1. You mention in your flaws of the ATOM2 study the confounding effects of varifocals prescribed to
some of the high-dose participants within their study but you do not describe what refractive
correction the participants within your own study will wear. Will this be full refractive correction with
single vision spectacle lenses/contact lenses/other? No details are described of whether
spectacles will be updated to the new correction where a difference is found within the trial; this
may be important with regard to potential under-correction of myopia.

2. Within your eligibility criteria, it is not clear how much myopic progression over the preceding year
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2. Within your eligibility criteria, it is not clear how much myopic progression over the preceding year
is considered enough? Within the information pack for parents the inclusion criteria states that
progression of -0.50D in the preceding year is required but this is not mentioned in the
publication. It would be helpful to know how much progression was occurring prior to participation
in the study and consider this in analyses. There are no references to why the eligibility criteria
were chosen; are these replicated from another RCT? It is perhaps unusual to see the inclusion
criteria extend to 16 years of age as the rate of progression of myopia will be fairly slow at this age
and the age range doesn’t align with that of other studies (e.g. ATOM 6-12 years). In the parent
information pack the eligibility criteria states that participants need to have myopia of <-1.50D but
in the article under review it is -1.00D or worse; why the discrepancy? It is also mentioned within
the parent information leaflet that inclusion requires a difference between the two eyes of less than
1D but this isn’t mentioned in the article, was this considered as an inclusion/exclusion criteria or
not?
3. You mention that good general health was a requirement for inclusion, did you consider
syndromes, e.g. Down syndrome, Marfan’s, Stickler’s that may have high levels of myopia and
respond differently to treatment? If so, were these exclusion criteria? Were diabetics excluded from
participation due to myopia shifts that can occur with poor control?
4. I also found a few discrepancies in the child assent and information leaflet. You state that “the
drops, which don’t sting or blur your vision, will need to be put into each eye every evening” but yet
you are asking the child to comment within a self-report discomfort questionnaire about these
symptoms. It also states that cyclopentolate 0.5% will be used to measure the participant’s need
for glasses but in the article you suggest you are using cyclopentolate 1.0%.
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Partly
Are the datasets clearly presented in a useable and accessible format?
Not applicable
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Epidemiology and aetiology of myopia and other refractive errors.
I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard.
Author Response 23 Sep 2019

Saoirse McCrann, Technological University Dublin, Ireland, Dublin, Ireland
Reviewer 1
This article describes the methodology for recruitment and data collection for the Myopia Outcome
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This article describes the methodology for recruitment and data collection for the Myopia Outcome
Study of Atropine in Children (MOSAIC), a double-masked, placebo-controlled, randomised
clinical trial. It aims to determine the efficacy, safety and mechanism of action of 0.01% atropine to
slow the progression of myopia in a predominantly white, European population of children aged six
to 16 years of age. Myopic children with progressing myopia will be recruited to the study and will
be randomly assigned to either the treatment group (0.01% atropine) or the placebo group and will
be reviewed every six months for a trial period of 2 years. The following year will either be a
washout period for the treatment group or the placebo group will receive 0.01% atropine daily.
There is clear rationale for the study with the worrying increase in prevalence of myopia across
Europe and the need for a better understanding of treatment therapies for controlling myopia
progression. The majority of previous clinical trials of atropine of varying concentrations have been
conducted in Asian populations where the progression of myopia differs to white, European
children, therefore similar studies need to be replicated to determine specific population efficacy
which will be answered by the proposed study design. The study methods are clearly described
although I had a few specific queries which could be addressed/clarified by the research group to
allow replication by others. There were also some discrepancies between the ‘extended data’
provided that didn’t tie up with that published in the article.
Reviewer comment 1
You mention in your flaws of the ATOM2 study the confounding effects of varifocals prescribed to
some of the high-dose participants within their study but you do not describe what refractive
correction the participants within your own study will wear. Will this be full refractive correction with
single vision spectacle lenses/contact lenses/other? No details are described of whether
spectacles will be updated to the new correction where a difference is found within the trial; this
may be important with regard to potential under-correction of myopia.
Author response 1
Thank you for this observation. Participants are advised to attend their
Optometrist/Ophthalmologist routinely throughout the MOSAIC trial and to update (if required) their
single vision spectacles/contact lenses to the full refractive correction. Parents/guardians are
advised if there is a difference between participants’ current prescription and the cycloplegic
refraction results at all study visit. Only single vision correction is permitted.
Reviewer comment 2
Within your eligibility criteria, it is not clear how much myopic progression over the preceding year
is considered enough? Within the information pack for parents the inclusion criteria states that
progression of -0.50D in the preceding year is required but this is not mentioned in the
publication. It would be helpful to know how much progression was occurring prior to participation
in the study and consider this in analyses. There are no references to why the eligibility criteria
were chosen; are these replicated from another RCT? It is perhaps unusual to see the inclusion
criteria extend to 16 years of age as the rate of progression of myopia will be fairly slow at this age
and the age range doesn’t align with that of other studies (e.g. ATOM 6-12 years). In the parent
information pack the eligibility criteria states that participants need to have myopia of <-1.50D but
in the article under review it is -1.00D or worse; why the discrepancy? It is also mentioned within
the parent information leaflet that inclusion requires a difference between the two eyes of less than
1D but this isn’t mentioned in the article, was this considered as an inclusion/exclusion criteria or
not?
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not?
Author response 2
Thank you for these observations, the noted differences arise from a review of our
inclusion/exclusion criteria post publication of the 2019 International Myopia Institute (IMI) reports.
As previous eye examinations may not have been consistently performed under cycloplegia and
due to prescribing variabilities among optometrists, myopia progression of -0.50D in the preceding
year is no longer an inclusion criterion. However, rate of progression in the year preceding study
commencement is monitored and will be factored into statistical analyses.
Inclusion criteria for MOSAIC is myopia of > -1.00D or worse in both eyes. A difference between
the two eyes of less than 1D is no longer an inclusion criterion.
In terms of age criteria, MOSAIC represents a large study sample across an age spectrum during
which myopia development and progression is most likely.[1] Irish electronic medical records
furthermore demonstrate the continued progression of myopia over 17 years of age. Although
there is no minimum progression requirement, we have made it very clear to referring optometrists
that progressive myopes are the target participant population. We felt it was important not to
exclude progressive myopes just to remain aligned with other studies.
Reviewer comment 3
You mention that good general health was a requirement for inclusion, did you consider
syndromes, e.g. Down syndrome, Marfan’s, Stickler’s that may have high levels of myopia and
respond differently to treatment? If so, were these exclusion criteria? Were diabetics excluded from
participation due to myopia shifts that can occur with poor control?
Author response 3
Any syndromic myopia is an exclusion criteria for the MOSAIC trial. Diabetes is not an exclusion
criteria once the participant is in good general and ocular health. Should a diabetic participant enrol
in MOSAIC, control will be explored as part of ongoing diabetes status and will be factored into our
analyses.
Reviewer comment 4
I also found a few discrepancies in the child assent and information leaflet. You state that “the
drops, which don’t sting or blur your vision, will need to be put into each eye every evening” but yet
you are asking the child to comment within a self-report discomfort questionnaire about these
symptoms. It also states that cyclopentolate 0.5% will be used to measure the participant’s need
for glasses but in the article you suggest you are using cyclopentolate 1.0%.
Author response 4
Thank you for this feedback. We will revisit the questionnaire and remove this statement. We are
using cyclopentolate 1.0% as recommended in the IMI – Clinical Myopia Control Trials and
Instrumentation Report.[2] Cycloplegia protocol is now specified in detail in the manuscript.
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